

Kevin Marsh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1618125/publications.pdf>

Version: 2024-02-01

120
papers

16,137
citations

28274

55
h-index

20961

115
g-index

125
all docs

125
docs citations

125
times ranked

11133
citing authors

#	ARTICLE	IF	CITATIONS
1	Mapping genetic markers of artemisinin resistance in <i>Plasmodium falciparum</i> malaria in Asia: a systematic review and spatiotemporal analysis. <i>Lancet Microbe</i> , The, 2022, 3, e184-e192.	7.3	16
2	Malaria protection due to sickle haemoglobin depends on parasite genotype. <i>Nature</i> , 2022, 602, 106-111.	27.8	36
3	Household poverty, schooling, stigma and quality of life in adolescents with epilepsy in rural Uganda. <i>Epilepsy and Behavior</i> , 2021, 114, 107584.	1.7	4
4	Individual-level variations in malaria susceptibility and acquisition of clinical protection. <i>Wellcome Open Research</i> , 2021, 6, 22.	1.8	6
5	An open dataset of <i>Plasmodium falciparum</i> genome variation in 7,000 worldwide samples. <i>Wellcome Open Research</i> , 2021, 6, 42.	1.8	97
6	Systemic and cerebrospinal fluid immune and complement activation in Ugandan children and adolescents with long-standing nodding syndrome: A case-control study. <i>Epilepsia Open</i> , 2021, 6, 297-309.	2.4	10
7	10-year longitudinal study of malaria in children: Insights into acquisition and maintenance of naturally acquired immunity. <i>Wellcome Open Research</i> , 2021, 6, 79.	1.8	7
8	Equity for excellence in academic institutions: a manifesto for change. <i>Wellcome Open Research</i> , 2021, 6, 142.	1.8	6
9	Epilepsy in <i>Onchocerca volvulus</i> Sero-Positive Patients From Northern Uganda—Clinical, EEG and Brain Imaging Features. <i>Frontiers in Neurology</i> , 2021, 12, 687281.	2.4	7
10	An open dataset of <i>Plasmodium falciparum</i> genome variation in 7,000 worldwide samples. <i>Wellcome Open Research</i> , 2021, 6, 42.	1.8	51
11	Risk Factors for Nodding Syndrome and Other Forms of Epilepsy in Northern Uganda: A Case-Control Study. <i>Pathogens</i> , 2021, 10, 1451.	2.8	9
12	Characterization of Naturally Acquired Immunity to a Panel of Antigens Expressed in Mature <i>P. falciparum</i> Gametocytes. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 774537.	3.9	10
13	The remaining unknowns: a mixed methods study of the current and global health research priorities for COVID-19. <i>BMJ Global Health</i> , 2020, 5, e003306.	4.7	37
14	Patients' preferences of cutaneous leishmaniasis treatment outcomes: Findings from an international qualitative study. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0007996.	3.0	14
15	<i>Plasmodium falciparum</i> Merozoite Associated Armadillo Protein (PfMAAP) Is Apically Localized in Free Merozoites and Antibodies Are Associated With Reduced Risk of Malaria. <i>Frontiers in Immunology</i> , 2020, 11, 505.	4.8	2
16	Antibody Responses to Crude Gametocyte Extract Predict <i>Plasmodium falciparum</i> Gametocyte Carriage in Kenya. <i>Frontiers in Immunology</i> , 2020, 11, 609474.	4.8	2
17	Funding and COVID-19 research priorities - are the research needs for Africa being met?. <i>AAS Open Research</i> , 2020, 3, 56.	1.5	18
18	Observational study: 27 years of severe malaria surveillance in Kilifi, Kenya. <i>BMC Medicine</i> , 2019, 17, 124.	5.5	33

#	ARTICLE	IF	CITATIONS
19	Antigenic cartography of immune responses to Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1). PLoS Pathogens, 2019, 15, e1007870.	4.7	6
20	IgM in human immunity to Plasmodium falciparum malaria. Science Advances, 2019, 5, eaax4489.	10.3	92
21	Gametocyte carriage in an era of changing malaria epidemiology: A 19-year analysis of a malaria longitudinal cohort. Wellcome Open Research, 2019, 4, 66.	1.8	10
22	Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study. Lancet, The, 2019, 393, 2146-2154.	13.7	111
23	Repeated clinical malaria episodes are associated with modification of the immune system in children. BMC Medicine, 2019, 17, 60.	5.5	37
24	Doxycycline for the treatment of nodding syndrome (DONS); the study protocol of a phase II randomised controlled trial. BMC Neurology, 2019, 19, 35.	1.8	14
25	Effect of 10-valent pneumococcal conjugate vaccine on the incidence of radiologically-confirmed pneumonia and clinically-defined pneumonia in Kenyan children: an interrupted time-series analysis. The Lancet Global Health, 2019, 7, e337-e346.	6.3	41
26	Few Plasmodium falciparum merozoite ligand and erythrocyte receptor pairs show evidence of balancing selection. Infection, Genetics and Evolution, 2019, 69, 235-245.	2.3	7
27	Use of gene expression studies to investigate the human immunological response to malaria infection. Malaria Journal, 2019, 18, 418.	2.3	11
28	Patient-centered benefit-risk analysis of transcatheter aortic valve replacement. F1000Research, 2019, 8, 394.	1.6	8
29	A seven-year study on the effect of the pre-erythrocytic malaria vaccine candidate RTS,S/AS01E on blood stage immunity in young Kenyan children. Wellcome Open Research, 2019, 4, 42.	1.8	10
30	Gametocyte carriage in an era of changing malaria epidemiology: A 19-year analysis of a malaria longitudinal cohort. Wellcome Open Research, 2019, 4, 66.	1.8	10
31	KILchip v1.0: A Novel Plasmodium falciparum Merozoite Protein Microarray to Facilitate Malaria Vaccine Candidate Prioritization. Frontiers in Immunology, 2018, 9, 2866.	4.8	26
32	Asymptomatic malaria parasitaemia and seizure control in children with nodding syndrome; a cross-sectional study. BMJ Open, 2018, 8, e023624.	1.9	8
33	Gene copy number variation in natural populations of Plasmodium falciparum in Eastern Africa. BMC Genomics, 2018, 19, 372.	2.8	12
34	Human candidate gene polymorphisms and risk of severe malaria in children in Kilifi, Kenya: a case-control association study. Lancet Haematology, the, 2018, 5, e333-e345.	4.6	90
35	An international qualitative study exploring patients' experiences of cutaneous leishmaniasis: study set-up and protocol. BMJ Open, 2018, 8, e021372.	1.9	6
36	Cord blood IgG and the risk of severe Plasmodium falciparum malaria in the first year of life. International Journal for Parasitology, 2017, 47, 153-162.	3.1	19

#	ARTICLE	IF	CITATIONS
37	Resistance to malaria through structural variation of red blood cell invasion receptors. <i>Science</i> , 2017, 356, .	12.6	135
38	Examining the human infectious reservoir for <i>Plasmodium falciparum</i> malaria in areas of differing transmission intensity. <i>Nature Communications</i> , 2017, 8, 1133.	12.8	174
39	Declining Malaria Transmission Differentially Impacts the Maintenance of Humoral Immunity to <i>Plasmodium falciparum</i> in Children. <i>Journal of Infectious Diseases</i> , 2017, 216, 887-898.	4.0	31
40	Hepatitis B virus infection as a neglected tropical disease. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005842.	3.0	79
41	Serological Conservation of Parasite-Infected Erythrocytes Predicts <i>Plasmodium falciparum</i> Erythrocyte Membrane Protein 1 Gene Expression but Not Severity of Childhood Malaria. <i>Infection and Immunity</i> , 2016, 84, 1331-1335.	2.2	7
42	A single point in protein trafficking by <i>Plasmodium falciparum</i> determines the expression of major antigens on the surface of infected erythrocytes targeted by human antibodies. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 4141-4158.	5.4	20
43	Targets and Mechanisms Associated with Protection from Severe <i>Plasmodium falciparum</i> Malaria in Kenyan Children. <i>Infection and Immunity</i> , 2016, 84, 950-963.	2.2	45
44	Malaria: Biology and Disease. <i>Cell</i> , 2016, 167, 610-624.	28.9	576
45	The effect of declining exposure on T cell-mediated immunity to <i>Plasmodium falciparum</i> – an epidemiological “natural experiment”. <i>BMC Medicine</i> , 2016, 14, 143.	5.5	20
46	Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children. <i>New England Journal of Medicine</i> , 2016, 374, 2519-2529.	27.0	336
47	Dynamics and role of antibodies to <i>Plasmodium falciparum</i> merozoite antigens in children living in two settings with differing malaria transmission intensity. <i>Vaccine</i> , 2016, 34, 160-166.	3.8	15
48	Age, Spatial, and Temporal Variations in Hospital Admissions with Malaria in Kilifi County, Kenya: A 25-Year Longitudinal Observational Study. <i>PLoS Medicine</i> , 2016, 13, e1002047.	8.4	68
49	Human Antibodies Fix Complement to Inhibit <i>Plasmodium falciparum</i> Invasion of Erythrocytes and Are Associated with Protection against Malaria. <i>Immunity</i> , 2015, 42, 580-590.	14.3	250
50	Multiple clinical episodes of <i>Plasmodium falciparum</i> malaria in a low transmission intensity setting: exposure versus immunity. <i>BMC Medicine</i> , 2015, 13, 114.	5.5	27
51	Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine. <i>New England Journal of Medicine</i> , 2015, 373, 2025-2037.	27.0	332
52	Identifying children with excess malaria episodes after adjusting for variation in exposure: identification from a longitudinal study using statistical count models. <i>BMC Medicine</i> , 2015, 13, 183.	5.5	25
53	Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. <i>Lancet Infectious Diseases</i> , 2015, 15, 1450-1458.	9.1	262
54	<i>Plasmodium falciparum</i> Malaria in Children Aged 0-2 Years: The Role of Foetal Haemoglobin and Maternal Antibodies to Two Asexual Malaria Vaccine Candidates (MSP3 and GLURP). <i>PLoS ONE</i> , 2014, 9, e107965.	2.5	30

#	ARTICLE	IF	CITATIONS
55	Limited antigenic diversity of Plasmodium falciparum apical membrane antigen 1 supports the development of effective multi-allele vaccines. BMC Medicine, 2014, 12, 183.	5.5	47
56	Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria. BMC Medicine, 2014, 12, 108.	5.5	206
57	New antigens for a multicomponent blood-stage malaria vaccine. Science Translational Medicine, 2014, 6, 247ra102.	12.4	157
58	A Genome Wide Association Study of Plasmodium falciparum Susceptibility to 22 Antimalarial Drugs in Kenya. PLoS ONE, 2014, 9, e96486.	2.5	27
59	Avidity of Anti-Circumsporozoite Antibodies following Vaccination with RTS,S/AS01E in Young Children. PLoS ONE, 2014, 9, e115126.	2.5	26
60	A micro-epidemiological analysis of febrile malaria in Coastal Kenya showing hotspots within hotspots. ELife, 2014, 3, e02130.	6.0	115
61	A threshold concentration of anti-merozoite antibodies is required for protection from clinical episodes of malaria. Vaccine, 2013, 31, 3936-3942.	3.8	71
62	Four-Year Efficacy of RTS,S/AS01E and Its Interaction with Malaria Exposure. New England Journal of Medicine, 2013, 368, 1111-1120.	27.0	240
63	Genome-wide screen identifies new candidate genes associated with artemisinin susceptibility in Plasmodium falciparum in Kenya. Scientific Reports, 2013, 3, 3318.	3.3	75
64	Profile: The Kilifi Health and Demographic Surveillance System (KHDSS). International Journal of Epidemiology, 2012, 41, 650-657.	1.9	295
65	A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants. New England Journal of Medicine, 2012, 367, 2284-2295.	27.0	653
66	Estimating Individual Exposure to Malaria Using Local Prevalence of Malaria Infection in the Field. PLoS ONE, 2012, 7, e32929.	2.5	38
67	Targets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunity. Journal of Clinical Investigation, 2012, 122, 3227-3238.	8.2	187
68	Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature, 2012, 487, 375-379.	27.8	450
69	T-Cell Responses to the DBLÎ±-Tag, a Short Semi-Conserved Region of the Plasmodium falciparum Membrane Erythrocyte Protein 1. PLoS ONE, 2012, 7, e30095.	2.5	11
70	Lack of Avidity Maturation of Merozoite Antigen-Specific Antibodies with Increasing Exposure to Plasmodium falciparum amongst Children and Adults Exposed to Endemic Malaria in Kenya. PLoS ONE, 2012, 7, e52939.	2.5	28
71	Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study. Lancet, The, 2011, 378, 1316-1323.	13.7	255
72	Effect of the Pre-erythrocytic Candidate Malaria Vaccine RTS,S/AS01E on Blood Stage Immunity in Young Children. Journal of Infectious Diseases, 2011, 204, 9-18.	4.0	60

#	ARTICLE	IF	CITATIONS
73	Stable and Unstable Malaria Hotspots in Longitudinal Cohort Studies in Kenya. PLoS Medicine, 2010, 7, e1000304.	8.4	221
74	Genome-wide and fine-resolution association analysis of malaria in West Africa. Nature Genetics, 2009, 41, 657-665.	21.4	345
75	<i>Plasmodium falciparum</i> var <i>W2</i> gene expression is modified by host immunity. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 21801-21806.	7.1	130
76	Immunity to malaria: more questions than answers. Nature Immunology, 2008, 9, 725-732.	14.5	724
77	<i>Plasmodium falciparum</i> antigenic variation. Mapping mosaic <i>var</i> gene sequences onto a network of shared, highly polymorphic sequence blocks. Molecular Microbiology, 2008, 68, 1519-1534.	2.5	91
78	Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya. Lancet, The, 2008, 372, 1555-1562.	13.7	386
79	Breadth and Magnitude of Antibody Responses to Multiple <i>Plasmodium falciparum</i> Merozoite Antigens Are Associated with Protection from Clinical Malaria. Infection and Immunity, 2008, 76, 2240-2248.	2.2	342
80	Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age. New England Journal of Medicine, 2008, 359, 2521-2532.	27.0	365
81	Relationship Between Exposure, Clinical Malaria, and Age in an Area of Changing Transmission Intensity. American Journal of Tropical Medicine and Hygiene, 2008, 79, 185-191.	1.4	76
82	Relationship between exposure, clinical malaria, and age in an area of changing transmission intensity. American Journal of Tropical Medicine and Hygiene, 2008, 79, 185-91.	1.4	64
83	The Induction and Persistence of T Cell IFN- γ Responses after Vaccination or Natural Exposure Is Suppressed by <i>Plasmodium falciparum</i> . Journal of Immunology, 2007, 179, 4193-4201.	0.8	88
84	Naturally acquired antibodies to polymorphic and conserved epitopes of <i>Plasmodium falciparum</i> merozoite surface protein 3. Parasite Immunology, 2007, 29, 387-394.	1.5	52
85	An approach to classifying sequence tags sampled from <i>Plasmodium falciparum</i> var genes. Molecular and Biochemical Parasitology, 2007, 154, 98-102.	1.1	55
86	Immune effector mechanisms in malaria. Parasite Immunology, 2006, 28, 51-60.	1.5	329
87	Contrasting signatures of selection on the <i>Plasmodium falciparum</i> erythrocyte binding antigen gene family. Molecular and Biochemical Parasitology, 2006, 149, 182-190.	1.1	32
88	A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya. PLOS Clinical Trials, 2006, 1, e29.	3.5	124
89	Sickle Cell Anaemia in East Africa: Preliminary Results from a Cohort Study.. Blood, 2006, 108, 3802-3802.	1.4	3
90	An Immune Basis for Malaria Protection by the Sickle Cell Trait. PLoS Medicine, 2005, 2, e128.	8.4	169

#	ARTICLE	IF	CITATIONS
91	Plasmodium falciparum Variant Surface Antigen Expression Patterns during Malaria. PLoS Pathogens, 2005, 1, e26.	4.7	158
92	Case Definitions of Clinical Malaria under Different Transmission Conditions in Kilifi District, Kenya. Journal of Infectious Diseases, 2005, 191, 1932-1939.	4.0	196
93	Sickle Cell Trait and the Risk of Plasmodium falciparum Malaria and Other Childhood Diseases. Journal of Infectious Diseases, 2005, 192, 178-186.	4.0	285
94	Clinical and Laboratory Features of Homozygous Sickle Cell Patients in Tanzania; Malaria, Infections and Cerebral Blood Flow Velocity.. Blood, 2005, 106, 3778-3778.	1.4	0
95	Protection against Clinical Malaria by Heterologous Immunoglobulin G Antibodies against Malaria-Infected Erythrocyte Variant Surface Antigens Requires Interaction with Asymptomatic Infections. Journal of Infectious Diseases, 2004, 190, 1527-1533.	4.0	58
96	Transient cross-reactive immune responses can orchestrate antigenic variation in malaria. Nature, 2004, 429, 555-558.	27.8	150
97	The use of cryopreserved mature trophozoites in assessing antibody recognition of variant surface antigens of Plasmodium falciparum-infected erythrocytes. Journal of Immunological Methods, 2004, 288, 9-18.	1.4	27
98	Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. Vaccine, 2004, 23, 718-728.	3.8	174
99	Malaria and Nutritional Status in Children Living on the Coast of Kenya. Scandinavian Journal of Immunology, 2004, 59, 615-616.	2.7	1
100	Management of severe malaria: implications for research. British Journal of Clinical Pharmacology, 2003, 55, 460-463.	2.4	2
101	The pathogenic basis of malaria. Nature, 2002, 415, 673-679.	27.8	1,423
102	Oxidative stress and erythrocyte damage in Kenyan children with severe Plasmodium falciparum malaria. British Journal of Haematology, 2001, 113, 486-491.	2.5	91
103	Chloroquine is not a risk factor for seizures in childhood cerebral malaria. Tropical Medicine and International Health, 2000, 5, 860-864.	2.3	13
104	Immunity to non-cerebral severe malaria is acquired after one or two infections. Nature Medicine, 1999, 5, 340-343.	30.7	433
105	Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. Nature Medicine, 1998, 4, 358-360.	30.7	578
106	Signs of Dehydration in Severe Childhood Malaria. Tropical Doctor, 1997, 27, 235-236.	0.5	9
107	PfEMP1, polymorphism and pathogenesis. Annals of Tropical Medicine and Parasitology, 1997, 91, 551-557.	1.6	44
108	Host-parasite interaction and morbidity in malaria endemic areas. Philosophical Transactions of the Royal Society B: Biological Sciences, 1997, 352, 1385-1394.	4.0	120

#	ARTICLE	IF	CITATIONS
109	Relation between severe malaria morbidity in children and level of Plasmodium falciparum transmission in Africa. Lancet, The, 1997, 349, 1650-1654.	13.7	561
110	30 years of science and technology: the example of malaria. Lancet, The, 1997, 349, S1-S2.	13.7	12
111	The pathogenesis of severe malaria in African children. Annals of Tropical Medicine and Parasitology, 1996, 90, 395-402.	1.6	93
112	Indicators of Life-Threatening Malaria in African Children. New England Journal of Medicine, 1995, 332, 1399-1404.	27.0	942
113	Plasmodium falciparum rosetting is associated with malaria severity in Kenya. Infection and Immunity, 1995, 63, 2323-2326.	2.2	302
114	Periodicity and space-time clustering of severe childhood malaria on the coast of Kenya. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1993, 87, 386-390.	1.8	135
115	Naturally acquired immunity to Plasmodium faldparum. Trends in Immunology, 1991, 12, A68-A71.	7.5	126
116	Malaria vaccines.. Archives of Disease in Childhood, 1988, 63, 468-470.	1.9	0
117	Antigens induced on erythrocytes by P. falciparum: expression of diverse and conserved determinants. Science, 1986, 231, 150-153.	12.6	335
118	Individual-level variations in malaria susceptibility and acquisition of clinical protection. Wellcome Open Research, 0, 6, 22.	1.8	4
119	Mortality in rural coastal Kenya measured using the Kilifi Health and Demographic Surveillance System: a 16-year descriptive analysis. Wellcome Open Research, 0, 6, 327.	1.8	3
120	10-year longitudinal study of malaria in children: Insights into acquisition and maintenance of naturally acquired immunity. Wellcome Open Research, 0, 6, 79.	1.8	4